Developing next-generation targeted cancer immunotherapy treatments
iOmx is a clinical-stage company that harnesses deep tumor and myeloid biology insights, along with its proprietary iOTargTM target screening platform, to generate novel treatments for the most prevalent solid tumor indications. The company is translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs. Focused on developing drugs with single agent activity, iOmx is creating potential new backbone therapies in a modality-open fashion. By applying its comprehensive drug discovery & development expertise iOmx is committed to shaping the future of cancer therapy.
iOmx is backed by international venture capital investors, such as ATHOS, Sofinnova Partners, Wellington Partners, MIG Capital as well as M Ventures. A EUR 65m Series B round was closed in September 2021.